Printed from Voxsanity (voxsanity.com.au) — NCT07640789 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 3 Lung Cancer Trial, Not Yet Recruiting
NCT07640789
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to voluntarily sign a consent form and follow the study requirements.
- People aged 18 to 75 years, of any gender.
- People whose doctors expect them to live for at least 3 months.
- People who have been diagnosed with stage III non-small cell lung cancer (a type of lung cancer) that cannot be removed by surgery.
- People whose tumor tissue has tested positive for one of a specific set of EGFR gene mutations (a change in the tumor's genetic make-up that can affect how it responds to treatment).
- People who are willing to provide either a stored tumor tissue sample from within the past year or a newly collected tissue sample.
- People who have received a specific type of chemotherapy combined with radiation therapy (called platinum-based radical chemoradiotherapy), where the chemotherapy included platinum plus one of a set of specified additional drugs.
- People who received a total radiation dose of 60 Gy (plus or minus 10%) as part of their chemoradiotherapy, before being enrolled in the trial.
- People whose side effects from prior chemoradiotherapy have mostly resolved, with any remaining side effects being mild (Grade 1 or lower on a standard medical scale).
- People who are generally well enough to carry out light daily activities, rated 0 or 1 on a standard health performance scale (ECOG scale).
- People who do not have serious heart problems, and whose heart pumping function (left ventricular ejection fraction) is at least 50%.
- People whose liver, kidneys, and blood counts are functioning at levels that meet the trial's requirements (confirm with trial site for specific values).
- People whose urine protein levels are within acceptable limits (confirm with trial site for specific values).
- Women who could become pregnant must have a negative blood pregnancy test within 7 days before starting treatment, must not be breastfeeding, and all enrolled participants must use reliable barrier contraception throughout treatment and for 7 months after treatment ends.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a type of lung cancer other than non-small cell lung cancer, including small cell lung cancer or mixed types.
- People who have received any other chemotherapy or radiation treatment for their lung cancer, apart from the radical chemoradiotherapy described in the inclusion criteria.
- People who have had major surgery within 4 weeks before the first study treatment dose.
- People who have previously been treated with certain targeted drug types, specifically antibody-drug conjugates (ADCs) that use topoisomerase I inhibitors, or any antibody or ADC targeting EGFR or HER3 proteins.
- People who have a history of serious heart disease or stroke-related (cerebrovascular) disease.
- People who have certain heart rhythm or electrical conduction problems, including a prolonged QTc interval, complete left bundle branch block, second- or third-degree heart block, or frequent uncontrolled irregular heartbeats.
- People who have experienced a blood clot event — such as a deep vein thrombosis, arterial clot, or pulmonary embolism — within the 6 months before screening.
- People who have been diagnosed with an active cancer (other than the lung cancer being treated in this trial) within the past 5 years.
- People whose high blood pressure remains poorly controlled despite taking two blood pressure medications.
- People whose blood sugar levels are poorly controlled.
- People who currently have radiation-related lung inflammation (radiation pneumonitis) rated Grade 2 or higher on a standard medical scale.
- People who have another ongoing lung condition that is causing significant breathing difficulties.
- People who have had a serious infection within 4 weeks before being enrolled in the trial.
- People who have large or symptom-causing fluid build-up in body cavities (such as around the lungs or abdomen).
- People whose scans show the tumor may be growing into or wrapping around major blood vessels in the chest, abdomen, neck, or throat.
- People who have had serious wounds, ulcers, or broken bones that have not healed within 4 weeks before signing the consent form.
- People who have had significant bleeding or a clear tendency to bleed within 4 weeks before signing the consent form.
- People who have a history of inflammatory bowel disease, large portions of bowel removed by surgery, or immune-related bowel inflammation.
- People who have had an allergic reaction to certain types of antibody-based medicines, or to any ingredient in the study drug.
- People who have previously had a stem cell transplant, either using their own cells or donor cells.
- People who test positive for HIV, or who have an active hepatitis B or hepatitis C infection.
- People who have a history of serious neurological or psychiatric conditions, or a history of substance misuse, alcohol dependence, or drug addiction.
- People who have received, or are planning to receive, a live vaccine within 28 days before being enrolled in the trial.
- People who the trial doctor considers unsuitable for the trial for any other medical or personal reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 December 2030
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.